Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
NCT06387199 on ClinicalTrials.gov · last registry update 2024-12-18
A small phase 2/phase 3 — 26 participants, against a typical 60. Due to report January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for diabetes and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2/P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Sponsor type
- Other
- Enrollment
- 26
- Started
- 2024-12-01
- Primary completion
- 2027-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo)
Conditions studied
Type 1 Diabetes · Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.